LeMaitre Vascular provides medical devices and human tissue cryopreservation services for the treatment of peripheral vascular disease, end-stage renal disease, and to a lesser extent cardiovascular disease. Co.'s portfolio of devices consists of products that are used in arteries and veins. Co.'s product offerings include a suite of biologic products, which include the XenoSure patch (bovine pericardium), CardioCel and VascuCel patches (bovine pericardium), ProCol graft (bovine mesenteric vein), Artegraft (bovine carotid artery), Omniflow II biosynthetic graft (ovine tissue and synthetic mesh) and the RestoreFlow Allograft cryopreserved graft (human cadaver tissue). The LMAT stock yearly return is shown above.
The yearly return on the LMAT stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the LMAT annual return calculation with any dividends reinvested as applicable (on ex-dates).
|